Rapport Therapeutics (RAPP) Net Income towards Common Stockholders (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Net Income towards Common Stockholders data on file, last reported at -$19.9 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 17.48% year-over-year to -$19.9 million in Q1 2026; TTM through Mar 2026 was -$107.3 million, a 34.6% decrease from a year earlier, with the FY2025 full-year figure at -$111.5 million, down 42.37% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$19.9 million, up from -$33.8 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for RAPP reached as high as -$6.4 million in Q2 2023 and fell as low as -$33.8 million in Q4 2025.
• Historically, Net Income towards Common Stockholders has averaged -$19.9 million across 4 years, with a median of -$19.9 million in 2024.
• Across the five-year window, Net Income towards Common Stockholders plunged 182.65% in 2024 and increased 17.48% in 2026, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$13.5 million in 2023, then sank by 47.79% to -$20.0 million in 2024, then tumbled by 68.98% to -$33.8 million in 2025, then jumped by 41.19% to -$19.9 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$19.9 million in Q1 2026, -$33.8 million in Q4 2025, and -$26.9 million in Q3 2025.